Displaying 1–25 of 10809 results for
Philadelphia-based Lannett announced it will close its Cody Laboratories subsidiary after failing to find a buyer.
Confidential settlement talks between Novartis and the U.S. government over allegations that the company paid doctors to market drugs were revealed when a letter written to U.S. District Judge was accidentally filed in the court docket.
The buzz may be around biologics, but the oral solid dose sector is still going strong
The Journal of the American Medical Association evaluated top-selling drugs finding that over a six year period, 78 percent of the drugs have seen an increase in costs by more than 50 percent.
The drama surrounding rival treatments for a rare autoimmune disease is mounting.
The FDA observations are piling up for one of India’s biggest generic drug manufacturers.
Supply Chain: The answer to today’s complexities lies in collaborative, sustainable supply chains.
The approval is based on a late-stage trial in which Keytruda showed a significant improvement in overall survival in cancer patients.
Thomas Schinecker is filling the shoes of the retiring Michael Heuer, who was holding the position on an interim basis.
The FDA grants accelerated approval to Roche’s drug combo for lymphoma.
For the first time, researchers have shown that an immunotherapy can temporarily block the development a genetic disease.
Merck & Co. announced it was buying privately held biopharmaceutical company, Tilos Therapeutics, in a deal that could be valued at up to $773 million.
New trials have shown the drug psilocybin - the active ingredient of magic mushrooms - to be effective in treating depression, and U.S. cities are starting to decriminalize it.
INTERPHEX 2019 conference recap
Insys Therapeutics has agreed to pay $225 million to settle the federal government's criminal and civil investigations into the company's marketing practices for it's fentanyl-based medication, Subsys.
The Trump administration announced that the federal government would sharply limit federal spending on medical research that uses tissue from aborted fetuses.
For the first time ever, the FDA has approved a medication to treat cluster headaches.
A few years ago, researchers inside Pfizer reportedly discovered that one of the company’s blockbuster drugs could be a breakthrough treatment for Alzheimer’s.
The German drugmaker will be providing an upfront payment, pharmaceutical R&D support and an investment $60 million.
The previously FDA-approved drug, Zerbaxa (ceftolozane and tazobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older.
The commercialization of a new drug follows a rigid path and applying for FDA approval can be a minefield of challenges. Here are expert tips for nailing your application.
Automation: Reaping the benefits from improved instrument verification and calibration procedures.
A treatment that targets a specific genetic mutation has proven to be effective in shrinking tumors in some patients with advanced lung cancer.
On Friday, the FDA listened to testimonies from over 100 stakeholders in the growing market for CBD, a non-psychoactive compound found in marijuana.
Gilead's Kite announced findings from new analyses of CAR-T treatments at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.